¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"low signal intensity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • analog signal
    ¾Æ³¯·Î±×½ÅÈ£
  • electric signal
    Àü±â½ÅÈ£
  • flow signal
    È帧½ÅÈ£, À¯µ¿½ÅÈ£
  • high signal
    °­ÇѽÅÈ£, °í½ÅÈ£
  • high velocity signal loss
    °í¼Ó½ÅÈ£¼Ò½Ç
  • MR signal
    ÀÚ±â°ø¸í½ÅÈ£
  • off-resonance signal
    ÀÌÅ»°ø¸í½ÅÈ£
  • signal
    ½ÅÈ£
  • signal alteration
    ½ÅÈ£º¯°æ
  • signal amplitude
    ½ÅÈ£ÁøÆø
  • signal anxiety
    ½ÅÈ£ºÒ¾È
  • signal averaging
    ½ÅÈ£Æò±Õ
  • signal homogeneity
    ½ÅÈ£±ÕÁú¼º
  • signal loss
    ½ÅÈ£¼Ò½Ç
  • signal oversampling
    ½ÅÈ£°ú´ÙÃßÃâ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low echo area
    ³·Àº¸Þ¾Æ¸®¿µ¿ª, Àú¿¡ÄÚ¿µ¿ª
  • low vision aid
    Àú½Ã·Âº¸Á¶±â
  • low pressure chamber
    Àú¾Ð½Ç
  • low forceps delivery
    ÀúÀ§Áý°ÔºÐ¸¸¼ú
  • low frequency deafness
    ÀúÁ֯ij­Ã», ÀúÁÖÆÄ±Í¸ÔÀ½
  • low residue diet
    ÀúÀÜ·ù½ÄÀÌ
  • low set ear
    óÁø±Í
  • low fever
    ¹Ì¿­
  • low-output heart failure
    Àú¹ÚÃâ½ÉÀåºÎÀü
  • low-pass filter
    ÀúÅë°ú°Å¸£°³, ÀúÅë°ú¿©°ú±â
  • low grade glioma
    ¾ç¼º½Å°æ¾Æ±³Á¾
  • low-tension glaucoma
    Àú¾È¾Ð³ì³»Àå
  • low pressure hydrocephalus
    Àú¾Ð¹°³úÁõ, Àú¾Ð¼öµÎÁõ
  • low renin hypertension
    Àú·¹´Ñ°íÇ÷¾Ð
  • low birth weight infant
    ÀúüÁßÃâ»ý¾Æ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • quadrature signal detection
    ±¸Àû ½ÅÈ£ ŽÁö
  • High intensity proton flow
    °í°­µµ ¾çÀÚ À¯µ¿
  • higher intensity
    °í°­µµ
  • intensity
    ¼¼±â, °­µµ(Ë­öô).
  • intensity
    ¼¼±â, °­µµ
  • intensity difference limen
    (À½ÀÇ)°­µµÆÇº°¿ªÄ¡
  • intensity difference thresheld
    °­µµÆÇº°(Ë­Óø÷÷ܬ)
  • intensity duration curve
    °­µµ±â°£°î¼±
  • intensity factor
    °­µµÀÎÀÚ
  • intensity level
    °­µµ¼öÁØ(Ë­öôâ©ñÞ).
  • intensity modulated radiation therapy
    °­µµº¯Á¶ ¹æ»ç¼±Ä¡·á
  • intensity of radiation
    ¹æ»ç¼±°­µµ
  • intensity of spectral lines
    ½ºÆåÆ®·³¼±ÀÇ °­µµ.
  • intensity of turbulence
    ¿Í·ùÀÇ °­µµ.
  • intensity variable
    °­µµº¯¼ö.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intensity of radiation
    ¹æ»ç¼±°­µµ
  • intensity of spectral lines
    ½ºÆåÆ®·³¼±ÀÇ °­µµ.
  • intensity of turbulence
    ¿Í·ùÀÇ °­µµ.
  • intensity variable
    °­µµº¯¼ö.
  • isosignal intensity
    µî½ÅÈ£ °­µµ
  • lower intensity
    Àú°­µµ
  • luminous intensity
    ±¤µµ(˴̬).
  • magnetic field intensity
    ÀÚÀå °­µµ
  • maximum intensity projection
    ÃÖ´ë°­µµ Åõ»ç
  • maximum safe intensity level
    ÃÖ´ë¾ÈÀü°­µµ.
  • peak intensity
    ÃÖ°í °­µµ (õÌÍÔ Ë­Óø), ÃÖ°í (õÌÍÔ) ¼¼±â
  • peak intensity
    ÃÖ°í °­µµ, ÃÖ°í ¼¼±â
  • pseudodiastole in high intensity proton flow
    °í°­µµ ¾çÀÚ À¯µ¿¿¡¼­ À§À̿ϱâ
  • radiant intensity
    ¹æ»ç°­µµ(Û¯ÞÒË­öô).
  • sound intensity
    À½°­µµ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low-energy compound
    Àú(î¸)¿¡³ÊÁöÈ­ÇÕ¹°(ûùùêÚª)
  • low-energy electron diffraction
    Àú(î¸)¿¡³ÊÁö ÀüÀÚȸÀý(ï³í­üÞï¹)
  • low-energy ion scattering
    Àú(î¸)¿¡³ÊÁö À̿ºлê(ÝÂߤ)
  • low-energy phophate acceptor
    Àú(î¸)¿¡³ÊÁö Àλê¼ö³³Ã¼(×òß«áôÒ¡ô÷)
  • low-frequency transduction
    Àúºóµµ ÇüÁúµµÀÔ(î¸ÞºÓøû¡òõÓôìý)
  • low-level promoter
    ÀúÀ§(î¸êÈ) ÇÁ·Î¸ðÅÍ
  • low-lipid lipoprotein
    ÀúÁöÁú Áö´Ü¹éÁú(î¸ò·òõò·Ó±ÛÜòõ)
  • low-order antibody
    ÀúÂ÷Ç×ü(î¸ó­ù÷ô÷)
  • low-potential iron protein
    ÀúÀüÀ§ ö´Ü¹éÁú(î¸ï³êÈôÑÓ±ÛÜòõ)
  • low-quality protein
    ÀúÁú´Ü¹éÁú(î¸òõÓ±ÛÜòõ)
  • low-speed sedimentaion equilibrium
    Àú¼Óħ°­ÆòÇü(î¸áÜöØË½øÁû¬)
  • low spin complex
    Àú(î¸)½ºÇÉ º¹ÇÕ¹°(ÜÜùêÚª)
  • low-temperature heat method
    Àú¿Â¿­¹ý(î¸è®æðÛö)
  • very low-density lipoprotein
    ÃÊÀú¹Ðµµ (õ±î¸ÚËÓø) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • very low-lipid lipoprotein
    ÃÊÀúÁöÁú(õ±î¸ò·òõ) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • isosignal intensity
    µî½ÅÈ£°­µµ
  • lower intensity
    Àú°­µµ
  • magnetic field intensity
    ÀÚÀå°­µµ
  • maximum intensity projection
    ÃÖ´ë°­µµÅõ»ç
  • peak intensity
    ÃÖ°í°­µµ, ÃÖ°í¼¼±â
  • pseudodiastole in high intensity proton flow
    °í°­µµ¾çÀÚÀ¯µ¿¿¡¼­ À§À̿ϱâ
  • analog signal
    ¾Æ³¯·Î±×½ÅÈ£
  • backscatter signal
    ÈĹæ»ê¶õ½ÅÈ£
  • clutter signal
    È¥¶õ½ÅÈ£
  • echo signal
    ¿¡ÄÚ½ÅÈ£
  • flow signal
    À¯µ¿½ÅÈ£
  • free induction decay signal
    ÀÚÀ¯À¯µµºØ±«½ÅÈ£
  • high signal
    °í½ÅÈ£
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
  • MR signal
    ÀÚ±â°ø¸í½ÅÈ£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LFT latex fixation test; latex flocculation test; left fronto-transverse [fetal position]; liver functio...
LPFS low-pass filtered signal
ELF elective low forceps; extremely low frequency
LBI low back injury; low serum-bound iron
LBP lipopolysaccharide-binding protein; low back pain; low blood pressure; lumbar back pain
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HIFU High Intensity Focused Ultrasound
HITS High Intensity Transient Signals
I Intensity
IMRT Intensity Modulated Radiation Therapy
IMRT Intensity Modulated Radiotherapy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bioelectric signal
    »ý¹°ÇÐÀû Àü±âÀû ½ÅÈ£
  • bright signal
    ¹àÀº »ó
  • echo signal
    ¿¡ÄÚ½ÅÈ£
  • expressive or signal output process
    Ç¥Çö¼º, ȤÀº ½ÅÈ£ÀÇ Ãâ·ÂÈ­ °úÁ¤
  • flow signal
    À¯µ¿ ½ÅÈ£
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
  • nociceptive signal
    Ä§ÇØ ¼ö¿ë¼º ½ÅÈ£, À¯ÇØ ¼ö¿ë¼º ½ÅÈ£
  • number of signal average
    ½ÅÈ£ Æò±Õ ȸ¼ö
  • quadrature signal detection
    ±¸Àû ½ÅÈ£ ŽÁö
  • signal alteration
    ½ÅÈ£ º¯°æ
  • signal averaging
    ½ÅÈ£ Æò±Õ
  • signal homogeneity
    ½ÅÈ£ ±ÕÀϼº
  • signal loss
    ½ÅÈ£ ¼Ò½Ç
  • signal peptide
    ½ÅÈ£ ÆéƼµå
  • signal symptom
    °æ°í Áõ»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
signal peptides Additional polypeptide sequence of 25 to 30 residues at the amino-terminal or carboxy-terminal end of proteins. The signal sequence signals the cellular fate or destination of a newly synthesised protein directing it to its ultimate destination in the cell. These leaders are recognised by the signal recognition particle and bound by specific receptor sites on the outer surface of the endoplasmic reticulum. They are then transported into the cisterna of the endoplasmic reticulum and from there directed to their ultimate destination in the cell. In prokaryotes, the signal peptides attach to the plasma membrane. These signal sequences are ultimately removed by specific peptidases.
(12 Dec 1998)
signal processing, computer-assisted Computer-assisted processing of electric, ultrasonic, or electronic signals to interpret function and activity.
(12 Dec 1998)
signal recognition particle A complex between a 7S RNA and six proteins. SRP binds to the nascent polypeptide chain of eukaryotic proteins with a signal sequence and halts further translation until the ribosome becomes associated with the rough endoplasmic reticulum. One of the SRP proteins (srp54) binds GTP and in association with 7SRNA and srp19 has GTPase activity.
(18 Nov 1997)
signal recognition particle receptor Receptor for the signal recognition particle (SRP) found in the membrane of the endoplasmic reticulum. Also called docking protein. Heterodimeric, both protomers having GTP binding capacity, though dissimilar binding sites. Not until the complex of SRP, ribosome, message and nascent polypeptide chain binds to the SRP receptor is the block to further chain elongation released and concurrently the SRP is released, leaving the ribosome attached to the endoplasmic reticulum membrane. Cotranslational transport of the polypeptide delivers it into the lumen of the ER.
(18 Nov 1997)
signal response coupling The cascade of processes by which an extracellular signal (typically a hormone or neurotransmitter) interacts with a receptor at the cell surface, causing a change in the level of a second messenger for example calcium or cyclic AMP) and ultimately effects a change in the cells functioning (for example: triggering glucose uptake or initiating cell division). Can also be applied to sensory signal transduction, for example of light at photoreceptors.
(18 Nov 1997)
signal sequence A peptide present on proteins that are destined either to be secreted or to be membrane components. It is usually at the N terminus and normally absent from the mature protein. Normally refers to the sequence (ca 20 amino acids) that interacts with signal recognition particle and directs the ribosome to the endoplasmic reticulum where co translational insertion takes place. Could also refer to sequences that direct post translational uptake by organelles. Signal peptides are highly hydrophobic but with some positively charged residues. The signal sequence is normally removed from the growing peptide chain by signal peptidase, a specific protease located on the cisternal face of the endoplasmic reticulum.
See: signal recognition particle.
(18 Nov 1997)
signal-to-noise ratio <microscopy> Also sometimes used as an abbreviation for serial number, can be somewhat confusing in the case of electronic equipment.
(05 Aug 1998)
signal transduction The cascade of processes by which an extracellular signal (typically a hormone or neurotransmitter) interacts with a receptor at the cell surface, causing a change in the level of a second messenger for example calcium or cyclic AMP) and ultimately effects a change in the cells functioning (for example: triggering glucose uptake or initiating cell division). Can also be applied to sensory signal transduction, for example of light at photoreceptors.
(18 Nov 1997)
signal void In magnetic resonance imaging, a region emitting no radiofrequency signal, either because there are no activated protons in the region (such as flowing blood) or because a different element predominates, particularly calcium.
(05 Mar 2000)
nuclear localization signal Short, predominantly basic amino acid sequences identified as nuclear import signals for some proteins. These sequences are believed to interact with specific receptors at nuclear pores.
(12 Dec 1998)
back pain, low Symptoms in the low back can relate to the bony lumbar spine, discs between the vertebrae, ligaments around the spine and discs, spinal cord and nerves, muscles of the low back, internal organs of the pelvis and abdomen, and the skin covering the lumbar area. The low back, or lumbar area, functions in structural support, movement, and protection of certain body tissue.
(12 Dec 1998)
blood sugar, low The sugar here is glucose. Low blood glucose constitutes hypoglycaemia. Hypoglycaemia is only significant when it is associated with symptoms. It has many causes including drugs, liver disease, surgical absence of the stomach, pre-diabetes, and rare tumours that release excess insulin.
(12 Dec 1998)
cardiac output, low A state of subnormal or depressed cardiac output, usually seen in patients with heart failure secondary to coronary artery, hypertensive, primary myocardial, valvular, or pericardial disease.
(12 Dec 1998)
very low density lipoprotein <biochemistry> A lipoprotein substances (combination of a fat and a protein) which acts as a carrier for cholesterol and fats (particularly triglycerides) in the bloodstream.
Elevations in very low density lipoprotein in the bloodstream are associated with an increased risk of atherosclerosis and coronary artery disease.
Acronym: VLDL
(18 Nov 1997)
Castellani-Low sign <clinical sign> A fine tremor of the tongue observed in sleeping sickness.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • home signal
    Àå³» ½ÅÈ£±â(¿ª±¸³» ÁøÀÔ ¿©ºÎ¸¦ ¾Ë¸²)
  • interval signal
    (¶óµð¿À ÇÁ·Î»çÀÌÀÇ)¼Û½Å°è¼Ó½ÅÈ£
  • signal
    ½ÅÈ£;±ºÈ£;µµÈ­¼±;¦ÆÐ¿¡°Ô º¸³»´Â ¾ÏÈ£ÀÇ ¼ö;½ÅÈ£(¿ë)ÀÇ;¶Ù¾î³­;ÈǸ¢ÇÑ;½ÅÈ£(±ºÈ£)·Î ¾Ë¸®´Ù;...ÀÇ ÀüÁ¶°¡ µÇ´Ù
  • signal tower
    (öµµÀÇ) ½ÅÈ£¼Ò
  • storm signal
    ÆøÇ³¿ì ½ÅÈ£
  • time signal
    ½Ãº¸
  • low
    ³·Àº,³·°Ô,õÇϰÔ,(¼Ò°¡)¿ï´Ù
  • low-minded
    ºñ¿­ÇÑ
  • Low Church
    Àú±³È¸ÆÄ(¿µ±¹ ±¹±³ÆÄÁß,±³È¸ÀÇ ±³¸®,ÀǽĿ¡ ÁßÁ¡À» µÎÁö ¾Ê´Â ÇÑ ÆÄ)
  • Low Churchman
    Àú±³È¸ÆÄÀÇ »ç¶÷
  • Low Countries
    Áö±ÝÀÇ BeneluxÀÇ ÃÑĪ
  • Low Mass
    Æò¹Ì»ç
  • Low Sunday
    ºÎȰÀý ´ÙÀ½ÀÇ ÀÏ¿äÀÏ
  • Middle Low German
    Áß¼¼(Áß±â) ÀúÁö µ¶ÀϾî(12-15¼¼±â)
  • low
    ³·Àº;ÀúÁöÀÇ;Àú±ÞÇÑ;ħ¿ïÇÑ;°ª½Ñ;ÀûÀº;°Ë¼ÒÇÑ;ÀúÁ¶ÀÇ;ÀúÀ½ÀÇ;be in ~ water µ·¿¡ ±ÃÇÏ´Ù;bring ~ ¼èÅðÄÉ ÇÏ´Ù;ÁÙÀÌ´Ù
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á